TLDR
- Can-Fite BioPharma successfully achieved the primary safety endpoint in its Phase 2a namodenoson trial for advanced pancreatic cancer without detecting new safety concerns.
- Twenty patients with heavily pretreated advanced pancreatic ductal adenocarcinoma (PDAC) participated in the clinical study.
- Approximately 33% of trial participants remained alive when the data snapshot was taken, with continued survival monitoring underway.
- The FDA has awarded namodenoson Orphan Drug Designation for pancreatic cancer indication.
- The company plans to share findings at future medical conferences, with more comprehensive survival information expected later.
On March 4, 2026, Can-Fite BioPharma announced favorable Phase 2a safety outcomes for its investigational treatment namodenoson in patients with advanced pancreatic cancer. The therapy demonstrated good tolerability among 20 previously treated participants, with no unexpected safety issues emerging. Approximately one-third of study subjects were still living at the time of the interim analysis, while survival tracking continues.
Namodenoson functions as a selective agonist of the A3 adenosine receptor. Its mechanism involves targeting a specific receptor that shows elevated expression in cancer and inflammatory cells compared to healthy tissue. The biotechnology company has been advancing this compound through development programs spanning various malignancies, including hepatocellular carcinoma.
Can-Fite BioPharma Ltd., CANF
The pancreatic cancer investigation utilized an open-label design and recruited participants who had previously experienced treatment failure with standard systemic therapies. This patient population presents significant therapeutic challenges. Pancreatic malignancies are among the deadliest cancers, and individuals who have exhausted conventional treatment approaches face extremely limited options.
The trial’s 20 enrollees represented a heterogeneous population with varying clinical characteristics, and many presented with metastatic disease. Several participants had undergone two or more previous treatment regimens, classifying them as a particularly vulnerable patient group.
Safety served as the study’s primary objective. Namodenoson successfully met this benchmark. Secondary objectives encompassed overall survival and progression-free survival metrics. Those outcome measures are still developing.
Orphan Drug Status
The U.S. Food and Drug Administration has conferred Orphan Drug Designation upon namodenoson for pancreatic cancer treatment. This regulatory classification applies to therapies addressing rare conditions and provides advantages such as extended market exclusivity and various development support mechanisms.
Can-Fite is simultaneously evaluating namodenoson in clinical trials for advanced hepatocellular carcinoma. This compound represents a cornerstone of the company’s development portfolio, alongside piclidenoson, which is being investigated for psoriasis treatment.
The biotechnology firm intends to disclose more mature survival information at forthcoming medical and scientific conferences. Neither specific venues nor presentation dates have been disclosed at this time.
Financial Picture
Can-Fite remains in the clinical development stage. The company has not achieved substantial revenue from commercialized products and continues to operate with negative earnings. Top-line revenue has contracted at a -41.5% compound annual rate across the preceding three years.
The operating margin stands at -1,595%, while the company registers an Altman Z-Score of -26.39, a financial metric indicating elevated distress risk. Institutional investor participation remains minimal at 3.49% ownership.
The current market valuation approximates $6.24 million, positioning CANF as a micro-cap equity. Shares experienced a single-day appreciation of +107.80% in the trading session following the March 4 announcement.
The most recent Wall Street analyst assessment on CANF is rated as Hold, accompanied by a $0.20 price objective. This valuation target presents a notable divergence from the stock’s dramatic upward movement following the clinical trial disclosure.
The post Can-Fite BioPharma (CANF) Stock Soars 107% on Positive Pancreatic Cancer Safety Data appeared first on Blockonomi.